La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.

Published Date: 28 Jun 2023

The U. S. For metastatic HRR-mutated castration-resistant prostate cancer (mCRPC), the Food and Drug Administration has approved Talzenna (talazoparib) in combination with enzalutamide.

Read Full News

Latest News

Single-dose radiation before surgery can eradicate breast cancer

A single, targeted high dose of radiation delivered before other treatments could completely eradicate tumors in most women with early-stage, operable hormone-positive breast cancer, according to a study led by UT Southwestern ...

Why palliative care goes hand in hand with treatment for people with cancer: Q&A

For many people with cancer and other serious diseases, palliative care is an important element of their journey.

Q&A: Odds of surviving cancer drop drastically when credit score dips

While past studies have explored how cancer patients' financial health influenced their risk of mortality, new research digs in deeper by zeroing in on objective data: credit scores.

Traces of bacteria inside brain tumors may affect tumor behavior

Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors. This discovery offers new insights into the environment in which brain tumors grow and sets ...

Cancer care crowdfunding increasingly common, but rarely successful

A growing number of desperate cancer survivors are turning to crowdfunding to help pay for their treatment and living expenses, a new study says.

Food insecurity linked to tumor growth in pediatric neuroblastoma

Neuroblastoma remains one of the deadliest childhood malignancies, accounting for a disproportionate number of pediatric cancer deaths worldwide.

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Latest News

A single, targeted high dose of radiation delivered before other treatments could completely eradicate tumors in most women with early-stage, operable hormone-positive breast cancer, according to a study led by UT Southwestern ...

For many people with cancer and other serious diseases, palliative care is an important element of their journey.

While past studies have explored how cancer patients' financial health influenced their risk of mortality, new research digs in deeper by zeroing in on objective data: credit scores.

Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors. This discovery offers new insights into the environment in which brain tumors grow and sets ...

A growing number of desperate cancer survivors are turning to crowdfunding to help pay for their treatment and living expenses, a new study says.

Neuroblastoma remains one of the deadliest childhood malignancies, accounting for a disproportionate number of pediatric cancer deaths worldwide.

News All Time

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

Bacteria are rapidly emerging as a new class of "living medicines" used to kill cancer cells.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

Aerobic and resistance exercise can significantly improve physical performance in patients living with metastatic breast cancer, according to new results presented at the Advanced Breast Cancer Eighth International Consensus ...

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately 200,000 people in the United States.

Advanced breast cancer patients living longer thanks to improvements in treatment and care

People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the average survival time for patients diagnosed in 2011, according to a major study of patient data in ...

Radiotherapy after mastectomy can be avoided, study finds

Radiotherapy can be safely omitted as a treatment for many breast cancer patients who have had a mastectomy and are taking anti-cancer drugs, a study shows.

Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects

By analyzing data from three clinical trials treating children with the brain tumor medulloblastoma, scientists at St. Jude Children's Research Hospital have designed an approach to safely reduce therapy, thereby lowering ...

Sustained reduction found in prostate cancer mortality with prostate-specific antigen screening

A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of overdiagnosis, or the detection ...

How access to specialized cancer centers affects glioblastoma outcomes

Glioblastoma is one of the most aggressive and complex brain cancers. It grows quickly, resists standard treatments, and often leaves patients and their families searching for every possible option.

Is global cancer care losing its human touch?

A new Lancet Oncology Commission highlights a growing "human crisis" in cancer care. Despite advances in treatment and increased survival rates, many patients worldwide are not receiving the compassionate, holistic support ...

Indoor hydroponic gardening can improve mental health and quality of life for cancer patients

Indoor hydroponic gardening—a method of growing plants using nutrient-rich water instead of soil—could help cancer patients develop better mental health, eat a healthier diet and enjoy a better overall quality of life.

Clinical trial sees dramatic results using radiation to treat breast cancer

Almost immediately after Theresa Greco was diagnosed with breast cancer in March, doctors asked her whether she wanted to participate in a clinical trial. The trial would do high-powered radiation targeted at her tumor prior ...

Dual-action mRNA vaccine takes aim at aggressive skin cancer

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting the protein essential to tumor cell growth and by adding a key signal to boost the immune system response. ...

For incarcerated people, study shows gaps exist in quality of cancer care

In the United States, the incarcerated population is aging. About 15% of incarcerated adults, or approximately 175,000 people, are now 55 years or older.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive molecular analysis of renal medullary carcinoma (RMC), a rare and aggressive ...

FDA approves Blenrep for relapsed or refractory multiple myeloma

The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.

Radiation therapy for patients with breast cancer

Radiation therapy is a common component of breast cancer treatment for patients. The high-powered beams of intense energy kill cancer cells and reduce the risk of the cancer recurring.

Recommended News For You

Should the UK introduce targeted prostate cancer screening? The case for and against

The discovery of drug combinations may increase the life expectancy of children with brain cancer.

Researchers discover cellular 'doorway' exploited by cancer-causing virus

La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.

Routine breast cancer screening can bring better outcomes for patients

A retrospective study examined the role of CA 19-9 and CEA in duodenal adenocarcinoma prognosis.

Drop in credit score after cancer diagnosis linked to increased mortality

Recommended Articles For You

Vaccines that can help prevent cancer 

A New Perspective on Spherocytosis: Uncovering Innovative Treatments 

Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care 

Understanding Drug-Induced Cardiotoxicity: Mechanisms, Impact, and Future Directions 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Survey shows cancer anxiety has impact well beyond the individual diagnosed

2.

Cancer care crowdfunding increasingly common, but rarely successful

3.

Novel radiotracer identifies biomarker for triple-negative breast cancer

4.

Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer

5.

June 20, 2023, Health Bulletin No. 12.

1.

Radioligand Therapy Advances: PSMA, Neuroendocrine, and Solid Tumor Clinical Insights

2.

Navigating the Complexities of Melanoma Staging: A Comprehensive Guide

3.

Navigating the Stages of Thyroid Cancer: A Guide for Patients

4.

Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology

5.

Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

2.

L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients

3.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

4.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective

5.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot